Standard BioTools Inc.

NasdaqGS:LAB Stock Report

Market Cap: US$466.2m

Standard BioTools Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:LAB Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
28 Feb 25BuyUS$5,134,321Casdin Capital, LLCCompany4,820,959US$1.07
27 Aug 24BuyUS$546,750Casdin Capital, LLCCompany250,000US$2.19
26 Aug 24BuyUS$1,546,237Casdin Capital, LLCCompany750,000US$2.15
21 Aug 24BuyUS$2,351,875Casdin Capital, LLCCompany1,250,000US$1.90
14 Aug 24BuyUS$1,913,520Casdin Capital, LLCCompany1,200,000US$1.59
14 Aug 24BuyUS$1,913,520Casdin Capital, LLCCompany1,200,000US$1.59
13 Aug 24BuyUS$2,559,641Casdin Capital, LLCCompany1,575,408US$1.64
08 Aug 24BuyUS$1,718,801Casdin Capital, LLCCompany1,069,562US$1.64
05 Aug 24BuyUS$1,948,680Casdin Capital, LLCCompany1,200,000US$1.63
23 May 24BuyUS$260,000Casdin Capital, LLCCompany100,000US$2.60
22 May 24BuyUS$1,541,795Casdin Capital, LLCCompany600,000US$2.58
17 May 24BuyUS$3,455,544Casdin Capital, LLCCompany1,352,072US$2.57

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of LAB?
Owner TypeNumber of SharesOwnership Percentage
Public Companies16,5150.00436%
Individual Insiders5,728,8251.51%
General Public56,293,26214.9%
Hedge Funds58,651,17015.5%
VC/PE Firms76,075,63620.1%
Institutions182,220,95448.1%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 79.71% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
20.1%
Casdin Capital, LLC
76,075,636US$93.6m6.77%7.65%
15.5%
Viking Global Investors LP
58,651,170US$72.1m0%0.25%
10.4%
Nippon Life India Asset Management Limited
39,296,310US$48.3m0%0.11%
6.56%
BlackRock, Inc.
24,857,850US$30.6m10.7%no data
4.53%
The Vanguard Group, Inc.
17,156,146US$21.1m-0.79%no data
4.15%
Morgan Stanley Investment Management Inc.
15,715,326US$19.3m14.4%0.02%
1.87%
Millennium Management LLC
7,081,711US$8.7m1.4%0.01%
1.84%
Geode Capital Management, LLC
6,975,221US$8.6m0.37%no data
1.75%
Nikko Asset Management Co., Ltd.
6,618,394US$8.1m-65.4%no data
1.73%
Tikvah Management LLC
6,551,058US$8.1m0%2.98%
1.66%
State Street Global Advisors, Inc.
6,290,000US$7.7m14.5%no data
1.45%
Hollow Brook Wealth Management LLC
5,503,381US$6.8m-0.53%2.15%
1.21%
Neuberger Berman Investment Advisers LLC
4,580,053US$5.6m-3.17%no data
0.88%
ARK Investment Management LLC
3,323,689US$4.1m-62.9%0.04%
0.85%
Barclays PLC Private Banking & Investment Banking Investment
3,230,851US$4.0m0.95%no data
0.83%
Mirabella Financial Services LLP
3,130,190US$3.9m0%no data
0.76%
Northern Trust Global Investments
2,875,160US$3.5m9.25%no data
0.71%
Eli Casdin
2,674,401US$3.3m-1.08%no data
0.62%
Charles Schwab Investment Management, Inc.
2,332,649US$2.9m0%no data
0.56%
Kent Lake PR LLC
2,131,345US$2.6m0%1.22%
0.5%
Pivotal BioVenture Partners LLC
1,883,179US$2.3m0%1.14%
0.43%
Slate Path Capital LP
1,615,000US$2.0m0%0.04%
0.38%
Royce & Associates, LP
1,455,503US$1.8m137%0.02%
0.3%
Morgan Stanley, Investment Banking and Brokerage Investments
1,118,202US$1.4m-24.9%no data
0.25%
UBS Asset Management AG
957,356US$1.2m70.9%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/25 08:43
End of Day Share Price 2025/04/25 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Standard BioTools Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sung Ji NamBTIG
Bryan BrokmeierCantor Fitzgerald & Co.
Shawn BevecDeutsche Bank